Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, closed a $102m Series C financing.

Led by Nello Mainolfi, PhD, co-founder, President and CEO, and Bruce Booth, DPhil, co-founder, Chairman of the Board (and partner at Atlas Venture), Kymera Therapeutics provides Pegasus™, a proprietary protein degradation platform to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases.

The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

The company is planning to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine targeted oncology indications.

It is also developing novel protein degrader therapies to target STAT3, an un-drugged oncogenic transcription factor as well as a driver of inflammation and fibrosis, in a range of cancers and chronic diseases. | To read full story, visit https://startuparound.com/read/1584041411.8962905/Kymera-Therapeutics-Raises-$102M-in-Series-C-Financing?ref=audio_experience